XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.31

+1.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert S. who wrote (16791)	4/13/2004 12:35:54 PM
From: Cacaito	Read Replies (8) of 17367

Agreed..." I do discount corporate statements, because of the Raptiva experience." xomaDna hyped to the max the effectiveness...it is NOT more effective than any other biologic out there. xomaDna hyped to the max safety issues...it is NOT safer, and it does indeed have its own share of VERY WORRISOME side effects. xomaDna hyped the penetration and marketing prowess...and they are NOT selling better than ANY of the other biologics, and the introduction was NOT better than Amevive. Let's see if they match Amevive first full year of $40 millions. ALL THIS DESPITE xomaDna being first and Biogen came from behind and accomplished the clinicals FIRST and regulatory affairs FIRST. Yes, We do need to discount the corporate statements about Raptiva from xomaDna! Biogen development of Antegren is a model of EXCELLENCE, especially with all the uncertainties coming from Elan, Biogen simply keep the program going steady ! 10 to 15 years ago xoma was in the $30s, progress has come and can hardly sustain $5s ! xoma is THE archetypical unreliable source per excellence! The "clinical benefits" leader of unapprovable drugs!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next